With the EU regulator already reviewing two coronavirus vaccines, could it beat the US FDA to the punch?
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.
A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.
The company’s chief financial officer leaves on the eve of its second-quarter earnings report; should investors be worried?